[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100404078":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":33,"responsibleParty":75,"collaborators":78,"id":86,"slug":10,"hasResults":87,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":87,"sex":93,"minAge":10,"maxAge":10,"enrollmentInfo":94,"targetDuration":97,"studyType":98,"phases":10,"briefSummary":99,"conditions":100,"keywords":106,"overallStatus":36,"whyStopped":10,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":117},{"fullName":5,"class":6},"Dana-Farber Cancer Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Variant in the TP53 Gene in blood or saliva",null,"Variant in the TP53 gene found on a blood or saliva test, have a relative with a variant in the TP53 gene, or because participant meets genetic testing criteria for Li-Fraumeni Syndrome (LFS) based on personal or family cancer history",[13],"Genetic: Data and Specimen Collection",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"GENETIC","Data and Specimen Collection","* Provide research team and access to relevant medical records\n* Answer short questionnaires periodically\n* Consider consenting to other optional parts of the research such as:\n* Providing up to 3 tubes (15ml) of blood at or near the time of consent, as approved by treating physician (optional).\n* Provide a saliva sample (optional).\n* Provide eyebrow hairs for analysis of DNA from the bulb (15-20 eyebrow plucks) (optional).\n* Provide permission for obtainment of stored tissue specimens from cancer or pre-cancer surgeries or biopsies from the pathology departments where they have been stored (optional).\n* Consider inviting relatives to join the study (optional).",[9],[21],{"name":22,"affiliation":5,"role":23},"Judy E Garber, MD, MPH","PRINCIPAL_INVESTIGATOR",[25,29],{"name":22,"role":26,"phone":27,"phoneExt":10,"email":28},"CONTACT","617-632-5770","jegarber@partners.org",{"name":30,"role":26,"phone":31,"phoneExt":10,"email":32},"Sophie Cahill, BS","617-632-4795","Sophie_Cahill@DFCI.HARVARD.edu",[34,53,64],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Boston Children's Hospital","RECRUITING","Boston","Massachusetts","02115","United States",{"type":42,"coordinates":43},"Point",[44,45],-71.05977,42.35843,{"lat":45,"lon":44},[48,52],{"name":49,"role":26,"phone":50,"phoneExt":10,"email":51},"JUNNE KAMIHARA, MD","888-733-4662","jkamihara@partners.org",{"name":49,"role":23,"phone":10,"phoneExt":10,"email":10},{"facility":54,"status":36,"city":37,"state":38,"zip":55,"country":40,"cosmosGeoPoint":56,"geoPoint":58,"contacts":59},"Brigham and Women's Hospital","02215",{"type":42,"coordinates":57},[44,45],{"lat":45,"lon":44},[60,63],{"name":61,"role":26,"phone":62,"phoneExt":10,"email":28},"Judy Garber, MD, MPH","617-632-2282",{"name":61,"role":23,"phone":10,"phoneExt":10,"email":10},{"facility":65,"status":36,"city":37,"state":38,"zip":55,"country":40,"cosmosGeoPoint":66,"geoPoint":68,"contacts":69},"Judy E. Garber",{"type":42,"coordinates":67},[44,45],{"lat":45,"lon":44},[70,74],{"name":71,"role":26,"phone":72,"phoneExt":10,"email":73},"Judy E. Garber, MD, MPH","617-763-8821","judy_garber@dfci.harvard.edu",{"name":61,"role":23,"phone":10,"phoneExt":10,"email":10},{"type":23,"investigatorFullName":76,"investigatorTitle":77,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Judy E. Garber, MD","Principal Investigator",[79,82,84],{"name":80,"class":81},"National Cancer Institute (NCI)","NIH",{"name":83,"class":6},"City of Hope Medical Center",{"name":85,"class":6},"Baylor College of Medicine","100404078",false,"NCT04541654","Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress","Li-Fraumeni & TP53: Understanding and Progress (LiFT UP)","LiFT_UP","Inclusion Criteria:\n\n* Individuals with a TP53 pathogenic or likely pathogenic variant identified in blood or saliva,\n* Individuals with variants of uncertain significance in TP53 may be eligible at the PI's discretion,\n* Blood relatives of individuals with a TP53 variant, who may be presumed obligate carriers or healthy controls,\n* Individuals who meet Classic or Chompret LFS criteria whether or not they have a TP53 gene variant,\n* Individuals may enroll their deceased relatives in the study.\n* Individuals with a known TP53 variant that is not LFS, but rather ACE, CHIP, or mosaicism.\n* Individuals participating in other LFS studies can still enroll in LiFT UP. Investigators may be collaborators.\n\nExclusion Criteria:\n\n* Individuals who decline to sign consent\n* Individuals who are unable to give consent or assent and are without a designated healthcare proxy","ALL",{"count":95,"type":96},1500,"ESTIMATED","5 Years","OBSERVATIONAL","The purpose of this research study is to learn more about variants in the TP53 gene both associated with Li-Fraumeni Syndrome (LFS), a hereditary cancer risk condition, and TP53 variants found in the blood for other reasons (e.g. ACE\u002FCHIP and mosaicism).",[101,102,103,104,105],"Li-Fraumeni Syndrome","TP53 Gene Mutation","Hereditary Cancer Syndrome","Clonal Hematopoiesis","Mosaicism",[101,107,103,104,105],"TP53 Gene Mutation (Variant)","2026-03-24",{"date":110,"type":111},"2026-03-27","ACTUAL",{"date":113,"type":111},"2020-09-15",{"date":115,"type":96},"2032-12-31",{"name":5,"class":6},3]